

**Virginia Medicaid**  
**Pharmacy & Therapeutics Committee Meeting**  
Agenda  
600 East Broad Street – 7<sup>th</sup> Floor Conference Rooms  
Richmond, VA 23219  
**Thursday, March 21, 2019 – 10 AM**  
**Rescheduled for Friday, March 29, 2019 10AM**

Welcome and Comments

Jennifer Lee, MD, Agency Director

Call to Order

Chethan Bachireddy, MD, Acting CMO, Chair

Drug Utilization Review (DUR) Board Report

Kathy Sardegna, MD

Approval of Minutes from September 26, 2018 Meeting

P&T Committee Members

PDL Management

P&T Committee Members

• **Potential New Therapeutic Class Review (PDL Category)**

- Calcitonin Gene-Related Peptide CGRP (Antimigraine Preparations)

• **PDL Phase I – New Drug Review (Therapeutic Class)**

**Brand Drugs**

- Arikayce™ (Antibiotics, Inhaled)
- Epidiolex®, Sympazan™ (Anticonvulsants)
- Abilify® Mycrite, Perseris™ (Antipsychotics)
- Bryhali™, Impoyz™, Nolix® (Steroids)
- Inveltys™, Dexycu™ (Ophthalmic -Anti-inflammatory Agents)
- Xelpros™ (Ophthalmic - Prostaglandin Analogs)
- Yupelri™ (COPD)

**Generics Drugs or New Dosage Forms**

- Ledipasvir/Sofosbuvir (generic Harvoni®), sofosbuvir/velpatasvir (generic Epclusa®) (Hepatitis C Agents)
- fenofibrate (generic Triglide®) (Lipotropics other)
- clobazam (generic Onfi® susp/tab) (Anticonvulsants)
- bupropion XL (generic Forfivo® XL) (Antidepressants)
- hydrocortisone butyrate (generic Locoid® lotion) desoximetasone (generic Topicort® spray) (Steroids)

• **PDL Phase II – Annual Review: Therapeutic Classes with Updates**

**Analgesics**

- Opioid Dependency (includes oral buprenorphine (Closed Class) & methadone)
- Opioids: Short Acting (includes combination drugs and lozenges)

**Antibiotics / Anti-Infectives**

- Antibiotics (topical)
- Antifungals (oral)
- Cephalosporins (Second and Third Generations)
- Gastrointestinal, Antibiotics
- Quinolones (Second and Third Generations)

**Antivirals**

- Antivirals for Herpes (HSV)
- Antivirals for Influenza

### **Blood Modifiers**

- Antihyperuricemics
- Erythropoiesis Stimulating Proteins

### **Cardiac**

- Anticoagulants (*includes oral agents, low molecular weight heparins & Factor XA Inhibitors*) (Closed Class)
- Platelet Aggregation Inhibitors

### **Central Nervous System**

- Antihyperkinesia/CNS Stimulants (Closed Class)
- Multiple Sclerosis Agents
- Neuropathic Pain

### **Contraceptives**

- Long-Acting Reversible Contraceptives (includes IUDs & injectables)

### **Dermatologic Agents (Topical)**

- Acne Agents (includes benzoyl peroxide, clindamycin, retinoids & combinations)
- Antivirals, topical
- Psoriasis Agents

### **Endocrine and Metabolic Agents**

- Androgenic Agents
- Bone Resorption Suppression and Related Agents (*includes bisphosphonates, calcitonins and others*)
- Hypoglycemics: Incretin Mimetics/Enhancers (*includes DPP-IV Inhibitors, GLP-1 Agonists & comb*) (Closed Class)
- Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Closed Class)

### **Immunological Agents**

- Self-administered Cytokine & CAM Antagonists with Related Agents including Methotrexate (*all indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis, Cryopyrin-Associated Periodic Syndromes (CAPS)*) (Closed class)

## **PDL Phase II – Annual Review: Therapeutic Classes without Significant Updates (reviewed by the Department)**

### **Analgesics**

- Antimigraine
- Non-Steroidal Anti-Inflammatory Drugs (NSAID) (includes Cox-2 inhibitors and topical agents)
- Opioids: Long Acting

### **Antibiotics / Anti-Infectives**

- Ketolides & Macrolides (Adult and Pediatric)
- Quinolones (Otic)

### **Dermatologic Agents (Topical)**

- Antifungal Agents
- Rosacea Agents

### **Central Nervous System**

- Non-Ergot Dopamine Receptor Agonists
- Skeletal Muscle Relaxants
- Smoking Cessation Agents

**Endocrine and Metabolic Agents**

- Estrogens (vaginal and oral)
- Hypoglycemics: Alpha-Glucosidase Inhibitors
- Hypoglycemics: Insulins
- Hypoglycemics: Meglitinides
- Hypoglycemics: Metformins
- Hypoglycemics: Sulfonylureas
- Hypoglycemics: Thiazolidinediones
- Pancreatic Enzymes
- Progestational Agent

**Confidential Meeting (Pricing Information Discussion)**

**P&T Committee Members & DMAS Staff**

**\*Criteria Discussion of Potential New Therapeutic Class**

**P&T Committee Members**

**Criteria Discussion of Phase I New Drugs**

**P&T Committee Members**

**Criteria Discussion of Phase II Drugs**

**P&T Committee Members**

*\*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

**Next Meeting – September 19, 2019 (tentative)**

**Chair**

.